Bluebird Bio shares fell as much as 8.28% premarket after confirming that Ayrmid failed to submit a binding proposal to acquire bluebird or secure necessary financing, despite a three-week engagement period and a timeline extension.
- Board reaffirmed its unanimous support for the existing acquisition agreement with Carlyle and SK Capital, urging shareholders to tender their shares by the May 2, 2025 deadline
- NOTE:
Bluebird Rises on Unsolicited Proposal from Ayrmid - NOTE:
Carlyle, SK to Buy Struggling Gene Therapy Firm Bluebird (1)
To view the source of this information, click
To contact the reporter on this story: